Overexpression of apoptosis-related protein, survivin, in fibroblasts from patients with systemic sclerosis
Recent studies suggest that, in addition to activation and hypersecretion of matrix components, fibroblasts from patients with systemic sclerosis (SSc) are resistant to apoptosis. Previous studies have shown that survivin, a member of inhibition of apoptosis (IAP) family, plays an important role in apoptosis resistance. Accordingly, we decided to study the expression of the most important members of IAP family in SSc fibroblasts, which can block apoptosis either by binding and inhibiting caspases or through caspase-independent mechanisms.
Skin biopsy samples were obtained from 19 patients with diffuse cutaneous SSc (DcSSc) and 16 healthy controls. Dermal fibroblasts were cultured and the total RNA was isolated from cells followed by cDNA synthesis. Real-time PCR was performed using SYBR Green PCR master mix and specific primers for cIAP1, cIAP2, XIAP, and Survivin mRNA quantification.
A significantly increased expression level of Survivin was observed in fibroblasts from SSc patients compared to controls (2.26-fold, P = 0.04). However, mRNA expression of cIAP1, cIAP2, and XIAP did not change significantly between cases and controls.
Our results showed that survivin is upregulated in SSc skin fibroblast which may lead to resistance to apoptosis. Further studies should be performed to reveal the role of survivin in apoptosis pathway of SSc fibroblasts.
KeywordsApoptosis Fibroblast IAP Survivin Systemic sclerosis
Individuals contributed to the accomplishment of this study are deeply acknowledged.
This study was financially supported by grants from the Shahid Sadoughi University of Medical Sciences (grant no. 93-3900) and Tehran University of Medical Sciences (grant no. 92-03-41-24652).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethic Committee of Tehran University of Medical Sciences and with the 1964 Helsinki declaration.
Informed consent was obtained from all individual participants included in the study.
- 1.Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Müller-Ladner U, Matucci-Cerinic M (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95(1):109–116. https://doi.org/10.1161/01.res.0000134644.89917.96 CrossRefGoogle Scholar
- 3.Tsuchiya N, Kawasaki A (2016) Genetics of systemic sclerosis. In: Systemic sclerosis. Springer, pp 81–92Google Scholar
- 4.Mahmoudi M, Fallahian F, Sobhani S, Ghoroghi S, Jamshidi A, Poursani S, Dolati M, Hosseinpour Z, Gharibdoost F (2017) Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Clin Rheumatol 36(4):853–862CrossRefGoogle Scholar
- 13.Crook NE, Clem R, Miller L (1993) An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 67(4):2168–2174Google Scholar
- 14.Birnbaum M, Clem R, Miller L (1994) An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol 68(4):2521–2528Google Scholar
- 24.Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005) The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res 24(3):415–421Google Scholar
- 27.LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205Google Scholar
- 39.Leask A (2008) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1:115–122Google Scholar